Moolec Science (MLEC) Net Income towards Common Stockholders (2022 - 2024)
Moolec Science (MLEC) reported Net Income towards Common Stockholders of $605241.0 for Q4 2024, down 51.13% on a YoY basis from $1.2 million in Q1 2024, and up 131.6% sequentially from -$1.9 million in Q3 2024.
Moolec Science (MLEC) Net Income towards Common Stockholders (2022 - 2024) Analysis & Trends
Moolec Science (MLEC) has 3 years of Net Income towards Common Stockholders data on file, last reported at $605241.0 in Q4 2024.
- For the quarter ending Q4 2024, Net Income towards Common Stockholders fell 51.13% year-over-year to $605241.0; the trailing twelve-month figure through Mar 2026 stood at $605241.0 (changed N/A YoY), and the FY2024 full-year result was -$32.9 million, down 181.3% from the prior year.
- Net Income towards Common Stockholders climbed to $605241.0 in Q4 2024, from -$1.9 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $1.2 million in Q4 2023 to a low of -$48.0 million in Q4 2022.
- A 3-year average of -$5.0 million and a median of -$1.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders jumped 102.58% in 2023 and plunged 291.05% in 2024, its largest moves.
- Tracing MLEC's Net Income towards Common Stockholders over 3 years: stood at -$48.0 million in 2022, then jumped by 102.58% to $1.2 million in 2023, then tumbled by 51.13% to $605241.0 in 2024.
- Business Quant data shows MLEC's Net Income towards Common Stockholders at $605241.0 in Q4 2024, -$1.9 million in Q3 2024, and -$2.5 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Moolec Science | 5.35 Bn | 5.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 605,241.00 |
| Sep 30, 2024 | -1.92 Mn |
| Jun 30, 2024 | -2.54 Mn |
| Mar 31, 2024 | -1.40 Mn |
| Dec 31, 2023 | 1.24 Mn |
| Sep 30, 2023 | -1.59 Mn |
| Jun 30, 2023 | -2.98 Mn |
| Mar 31, 2023 | -358,578.00 |
| Dec 31, 2022 | -47.96 Mn |
| Sep 30, 2022 | -721,426.00 |
| Jun 30, 2022 | -1.52 Mn |
| Mar 31, 2022 | -1.17 Mn |